|
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer Clinical research trials and Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer. Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer  Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
For Condition: Colorectal Cancer
Status: No longer recruiting
Sponsor(s): Genentech ,
Synopsis: The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Subjects must fulfill all of the following criteria to be eligible for study entry: - Signed informed consent - At least 18 years of age - Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum Resected or biopsied primary tumors or metastatic site will serve as the basis for histologic confirmation. - Measurable disease (defined as at least one dimension >2 cm [>1 cm on spiral CT scans]) - ECOG performance status of 0 or 1 - Life expectancy >3 months - Use of an effective means of contraception in men and in women of childbearing potential - Ability to comply with study and follow-up procedures
Total Enrollment:
Location and Contact Information:
Indiana University Cancer Pavilion
Indianapolis, Indiana, 46202
United States
Johns Hopkins Oncology Center
Baltimore, Maryland, 21231-1000
United States
Mary Crowley Medical Research Center
Dallas, Texas, 75246-2006
United States
Additional Information:
Study ID Numbers: OSI2520G;
Study Start Date: October 2002
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047762
Other Colorectal Cancer Studies:
1. Phase III Study of Irinotecan and Cetuximab vs Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Cancer
2. Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
3. Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
4. A Study of ABT-751 in Patients With Colorectal Cancer
5. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
Related Studies:
Other Colorectal Cancer Clinical Trials
Other Indiana Clinical Trials
Other Indianapolis Clinical Trials
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
|
|
|
|
|
|
|
|
